Soluble CD30 and toxicities of H22xKi-4
| Patient no. . | Dose level, mg/m2/d . | sCD30 pretherapy, U/mL . | sCD30 after second course, U/mL . | Tachycardia, grade . | Hypotension, grade . | Fever, grade . | Chills, grade . | Myalgia, grade . | Fatigue, grade . | HABA* . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 334 | 321 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
| 2 | 2.5 | 39.6 | 3.7 | 1 | 1 | 1 | 0 | 0 | 1 | 0 |
| 3 | 5 | 145.4 | 6.1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| 4 | 10 | 8.8 | 2.3 | 1 | 0 | 0 | 1 | 0 | 1 | 32 768 |
| 5 | 20 | 1.7 | 0.1 | 1 | 1 | 2 | 1 | 0 | 1 | 32 |
| 6 | 20 | 87.4 | 1.8 | 0 | 0 | 0 | 0 | 0 | 1 | 64 |
| 7 | 20 | 25 | Not detectable | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| 8 | 20 | 3.2 | 5.9 | 1 | 0 | 2 | 1 | 1 | 1 | 64 |
| 9 | 20 | 7.7 | Not detectable | 0 | 0 | 0 | 0 | 1 | 1 | 8 |
| 10 | 20 | 0.1 | 0.1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 024 |
| Patient no. . | Dose level, mg/m2/d . | sCD30 pretherapy, U/mL . | sCD30 after second course, U/mL . | Tachycardia, grade . | Hypotension, grade . | Fever, grade . | Chills, grade . | Myalgia, grade . | Fatigue, grade . | HABA* . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 334 | 321 | 1 | 1 | 0 | 0 | 0 | 1 | 0 |
| 2 | 2.5 | 39.6 | 3.7 | 1 | 1 | 1 | 0 | 0 | 1 | 0 |
| 3 | 5 | 145.4 | 6.1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| 4 | 10 | 8.8 | 2.3 | 1 | 0 | 0 | 1 | 0 | 1 | 32 768 |
| 5 | 20 | 1.7 | 0.1 | 1 | 1 | 2 | 1 | 0 | 1 | 32 |
| 6 | 20 | 87.4 | 1.8 | 0 | 0 | 0 | 0 | 0 | 1 | 64 |
| 7 | 20 | 25 | Not detectable | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| 8 | 20 | 3.2 | 5.9 | 1 | 0 | 2 | 1 | 1 | 1 | 64 |
| 9 | 20 | 7.7 | Not detectable | 0 | 0 | 0 | 0 | 1 | 1 | 8 |
| 10 | 20 | 0.1 | 0.1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 024 |
X-fold increase at the end of therapy compared with baseline.